# OnCo record nct06856837 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct06856837/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct06856837", "NCT06856837" ;
  schema:name "- IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorec"@en ;
  schema:description "A phase 2 trial of fruquintinib, tislelizumab, trifluridine/tipiracil and bevacizumab (glioblastoma use) in colorectal cancer, run by Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct06856837/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06856837> ;
  onco:status "recruiting" ;
  onco:tag "ctgov-ingest", "colorectal-deep-dive" ;
  onco:phase "2" ;
  onco:cancers <https://onco.cc/cancers/rectal-cancer/>, <https://onco.cc/cancers/colon-cancer/>, <https://onco.cc/cancers/msi-high-colorectal/> ;
  onco:technologies <https://onco.cc/technologies/antiangiogenic/>, <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/fruquintinib/>, <https://onco.cc/drugs/tislelizumab/>, <https://onco.cc/drugs/trifluridine-tipiracil/>, <https://onco.cc/drugs/bevacizumab-glioma/> .